Skip to main content
Altuviiio logo

ALTUVIIIO® Patient Experiences 


“He hasn't had a breakthrough or joint bleed since being on ALTUVIIIO!”
 

Considering the switch

I realized we needed a higher level of protection when Harrison was getting bumps and still having to get factor while on subcutaneous prophylaxis. When choosing a treatment option for Harrison, we wanted to limit how frequently he was getting hurt without stopping him from being the funny, sweet kid who loves to sing and play T-ball. It’s always nerve-racking leaving the treatment you are currently on in hopes that the next product will be better. I was hopeful and remained positive toward a brighter future!
 

Working with Harrison’s care team

We had a detailed conversation with his hematologist about the benefits of ALTUVIIIO and how it works, as well as the most common side effects. They listened to my requests on how many times I wanted my son's factor levels checked throughout the week to know what his levels were on any given day.
 

The right fit for us

The effective bleed protection that ALTUVIIIO demonstrated in studies, and the once-weekly infusion, make it the right fit for Harrison and our family. One time, my son fell off his bike and knocked out two teeth. One dose in the middle of the week in between his infusions was all it took to resolve his bleed!

This testimonial reflects one patient’s experience and has not been clinically evaluated. It is not intended to imply typical outcomes or substitute for clinical evidence. Ashley is a promotional speaker compensated by Sanofi. 

Discover More Patient Experiences

Indication

ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with Hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment & control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII are possible following administration of ALTUVIIIO. Neutralizing antibodies were not reported in the clinical trials. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

© 2025 Sanofi. All rights reserved. ALTUVIIIO, MyALTUVIIIO, and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2508205-v1.0-11/2025 Last Updated: November 2025